Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.

Abstract:

:Gastric acid suppression is the most effective medical therapy to control acidic gastro-oesophageal reflux: individuals in whom therapy fails usually have inadequate acid suppression. Twenty-four-hour intragastric pH-metry measures the percentage of time that gastric pH is above 4 or 3, the critical thresholds for tissue damage and symptom generation in the distal oesophagus. Effective medical therapy must control gastric acidity throughout the daytime, including the postprandial period. It is therefore useful to report the percentage of patients in whom gastric acidity is controlled above pH 4 for at least 16 out of 24 h. Esomeprazole was compared with standard-dose proton pump inhibitors in healthy volunteers and patients with gastro-oesophageal reflux disease. Esomeprazole, 40 mg daily, was significantly more effective at controlling gastric acidity above pH 4 for more than 16 h than lansoprazole, 30 mg daily (38% of individuals vs. 5%, respectively). Esomeprazole, 40 mg daily, also suppressed gastric acidity more effectively and in more individuals than pantoprazole, 40 mg daily, and rabeprazole, 20 mg daily. Esomeprazole, 20 mg daily, was significantly more effective at controlling gastric acidity than lansoprazole, 15 mg daily. The improved acid control with esomeprazole compared with other proton pump inhibitors is likely to result in superior healing rates and improved symptom relief, with fewer therapy-resistant patients.

journal_name

Aliment Pharmacol Ther

authors

Hatlebakk JG

doi

10.1046/j.1365-2036.17.s1.3.x

subject

Has Abstract

pub_date

2003-02-01 00:00:00

pages

10-5; discussion 16-7

eissn

0269-2813

issn

1365-2036

pii

196

journal_volume

17 Suppl 1

pub_type

杂志文章,评审
  • Review article: historic changes of Helicobacter pylori-associated diseases.

    abstract:BACKGROUND:The long-term time trends of multiple gastrointestinal diseases are characterised by a striking rise and fall. These temporal changes provide important clues about disease aetiology. AIM:To highlight the importance of Helicobacter pylori infection in shaping the temporal trends of many common gastrointestin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1111/apt.12380

    authors: Sonnenberg A

    更新日期:2013-08-01 00:00:00

  • Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

    abstract:BACKGROUND:Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C virus (HCV). AIM:To evaluate the long-term health economic outcomes of sofosbuvir + pegylated interferon alfa/ribavirin (pegIFN/RBV) compared with current treatments in patients inf...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12871

    authors: Saab S,Gordon SC,Park H,Sulkowski M,Ahmed A,Younossi Z

    更新日期:2014-09-01 00:00:00

  • Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

    abstract:BACKGROUND:Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia. AIM:To assess utility of these markers in a Western population. METHODS:SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prev...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14471

    authors: Song M,Camargo MC,Weinstein SJ,Murphy G,Freedman ND,Koshiol J,Stolzenberg-Solomon RZ,Abnet CC,Männistö S,Albanes D,Rabkin CS

    更新日期:2018-02-01 00:00:00

  • An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.

    abstract::Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily. In 40 patients (95.2%) the ulcers healed within 2-12 weeks. In the remaining 2 p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1993.tb00589.x

    authors: Brunner G,Arnold R,Hennig U,Fuchs W

    更新日期:1993-01-01 00:00:00

  • Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.

    abstract:BACKGROUND:Approximately one third of patients with acute severe ulcerative colitis (ASUC) fail response to steroids. Ciclosporin and anti-TNFα are proven second-line therapies, but evidence of their efficacy has come mainly from tertiary centres and/or selective clinical trial recruitment. AIM:To assess ASUC outcomes...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12473

    authors: Lynch RW,Lowe D,Protheroe A,Driscoll R,Rhodes JM,Arnott ID

    更新日期:2013-10-01 00:00:00

  • Functional dyspepsia: the economic impact to patients.

    abstract:BACKGROUND:Although highly prevalent, little is known about the economic impact of functional dyspepsia (FD). AIMS:To quantify FD patients' health care utilisation patterns and to estimate direct and indirect costs of FD to patients. METHODS:ICD-9 codes identified adult patients with dyspepsia. A validated questionna...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12355

    authors: Lacy BE,Weiser KT,Kennedy AT,Crowell MD,Talley NJ

    更新日期:2013-07-01 00:00:00

  • Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) frequently affects women during their reproductive years. Pregnancy outcome in women with IBD is well described, particularly in retrospective studies. AIM:To evaluate the pregnancy outcome in patients with IBD in a prospective European multicentre case-control study. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2011.04794.x

    authors: Bortoli A,Pedersen N,Duricova D,D'Inca R,Gionchetti P,Panelli MR,Ardizzone S,Sanroman AL,Gisbert JP,Arena I,Riegler G,Marrollo M,Valpiani D,Corbellini A,Segato S,Castiglione F,Munkholm P,European Crohn-Colitis Organisat

    更新日期:2011-10-01 00:00:00

  • A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.

    abstract:BACKGROUND:One-week proton pump inhibitor-based triple therapies are very popular in the US despite limited US data documenting efficacy. We assessed 1-week proton pump inhibitor triple therapies for Helicobacter pylori, and compared them to dual antibiotic therapies (to assess benefit of omeprazole) and to omeprazole-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1997.00230.x

    authors: Laine L,Frantz JE,Baker A,Neil GA

    更新日期:1997-10-01 00:00:00

  • Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

    abstract:BACKGROUND:Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM:To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14328

    authors: Lin M,Kramer J,White D,Cao Y,Tavakoli-Tabasi S,Madu S,Smith D,Asch SM,El-Serag HB,Kanwal F

    更新日期:2017-11-01 00:00:00

  • Identifying responders to acid suppression in dyspepsia using a random starting day trial.

    abstract:BACKGROUND:Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely. This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2000.00866.x

    authors: Bytzer P,Hansen JM,Rune S,Bonnevie O,Breinstrup H,Funch-Jensen P,Matzen P,Meineche-Schmidt V,Schaffalitzky De Muckadell OB

    更新日期:2000-11-01 00:00:00

  • Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

    abstract:BACKGROUND:Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss, dehydration and malnutrition due to inadequate caloric and fluid intake. TZP-101 (ulimorelin) is a ghrelin receptor agonist that accelerates gastric emptying and improves upper gastrointestin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04567.x

    authors: Wo JM,Ejskjaer N,Hellström PM,Malik RA,Pezzullo JC,Shaughnessy L,Charlton P,Kosutic G,McCallum RW

    更新日期:2011-03-01 00:00:00

  • Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.

    abstract:BACKGROUND:This randomized, double-blind, multicentre study compared lansoprazole with placebo for symptomatic relief of patients with non-erosive gastro-oesophageal reflux disease (GERD). METHODS:214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1999.00558.x

    authors: Richter JE,Kovacs TO,Greski-Rose PA,Huang section sign B,Fisher R

    更新日期:1999-06-01 00:00:00

  • The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.

    abstract:AIM:To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer. METHODS:This was a double-blind, randomized study in 15 centres across Canada. Patients (n = 149)...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1999.00471.x

    authors: Zanten SJ,Bradette M,Farley A,Leddin D,Lind T,Unge P,Bayerdörffer E,Spiller RC,O'Morain C,Sipponen P,Wrangstadh M,Zeijlon L,Sinclair P

    更新日期:1999-03-01 00:00:00

  • Sedation in digestive endoscopy: the Athens international position statements.

    abstract:BACKGROUND:Guidelines and practice standards for sedation in endoscopy have been developed by various national professional societies. No attempt has been made to assess consensus among internationally recognized experts in this field. AIM:To identify areas of consensus and dissent among international experts on a bro...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 共识发展会议,杂志文章

    doi:10.1111/j.1365-2036.2010.04352.x

    authors: Cohen LB,Ladas SD,Vargo JJ,Paspatis GA,Bjorkman DJ,Van der Linden P,Axon AT,Axon AE,Bamias G,Despott E,Dinis-Ribeiro M,Fassoulaki A,Hofmann N,Karagiannis JA,Karamanolis D,Maurer W,O'Connor A,Paraskeva K,Schreiber F,

    更新日期:2010-08-01 00:00:00

  • Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.

    abstract:BACKGROUND:Previous data have indicated low bone formation as a mechanism of osteoporosis in inflammatory bowel disease. Fluoride can stimulate bone formation. AIM:To assess the effect of fluoride supplementation on lumbar spine bone mineral density in osteoporotic patients with inflammatory bowel disease treated in p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2002.01247.x

    authors: Abitbol V,Mary JY,Roux C,Soulé JC,Belaiche J,Dupas JL,Gendre JP,Lerebours E,Chaussade S,Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

    更新日期:2002-05-01 00:00:00

  • Depression in cirrhosis - a prospective evaluation of the prevalence, predictors and development of a screening nomogram.

    abstract:BACKGROUND:Depression is associated with substantial morbidity and mortality in cirrhosis, but is underdiagnosed and undertreated. AIMS:Using the Mini International Neuropsychiatric Interview (MINI) as a gold-standard, to determine prevalence, predictors, and outcomes of depression, and to develop a screening nomogram...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15068

    authors: Buganza-Torio E,Mitchell N,Abraldes JG,Thomas L,Ma M,Bailey RJ,Tandon P

    更新日期:2019-01-01 00:00:00

  • Review article: management of hepatic disease following haematopoietic cell transplant.

    abstract::Hepatic diseases are common complications of haematopoietic cell transplant. The causes are multiple: myeloablative conditioning regimens may cause sinusoidal injury; acute and chronic graft-versus-host disease lead to damaged hepatocytes and small bile ducts; microcrystalline deposits in the gall bladder can cause bi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03001.x

    authors: McDonald GB

    更新日期:2006-08-01 00:00:00

  • Effect of low-dose omeprazole on gastric acid secretion in duodenal ulcer patients.

    abstract::The effect of 7 days of oral dosing with 5 mg day-1 and 20 mg day-1 omeprazole on basal and pentagastrin-stimulated gastric acid output was studied in nine duodenal ulcer patients. Basal acid output measured 5-6 h post-dosing was decreased by a mean of 75% on 5 mg omeprazole and by 90% on 20 mg omeprazole (P less than...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00696.x

    authors: McLauchlan G,Crean GP,McColl KE

    更新日期:1988-06-01 00:00:00

  • Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

    abstract:BACKGROUND:Saccharomyces boulardii, a well-studied probiotic, can be effective in inflammatory gastrointestinal diseases with diverse pathophysiology, such as inflammatory bowel disease (IBD), and bacterially mediated or enterotoxin-mediated diarrhoea and inflammation. AIM:To discuss the mechanisms of action involved ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04102.x

    authors: Pothoulakis C

    更新日期:2009-10-15 00:00:00

  • Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population.

    abstract:BACKGROUND:The incidence of irritable bowel syndrome is uncertain. We aimed to determine the incidence of clinically diagnosed irritable bowel syndrome in the community. METHODS:Using the Rochester Epidemiology Project, all diagnoses of irritable bowel syndrome made among adult residents of Olmsted County, Minnesota, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01938.x

    authors: Locke GR 3rd,Yawn BP,Wollan PC,Melton LJ 3rd,Lydick E,Talley NJ

    更新日期:2004-05-01 00:00:00

  • Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.

    abstract:BACKGROUND:Proton pump inhibitors (PPIs) are the preferred agents for the prevention of aspirin-associated upper gastrointestinal bleeding (UGIB). Data are limited to determine whether PPIs are being used to reduce UGIB risk. AIM:To evaluate the implementation of PPI treatment to reduce the GI risk in two cardiology c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2010.04393.x

    authors: Casado-Arroyo R,Scheiman JM,Polo-Tomas M,Saini SD,Del Rio A,Guastello E,Lanas A

    更新日期:2010-09-01 00:00:00

  • Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.

    abstract::Unfractioned heparin was recently reported to be beneficial in the treatment of inflammatory bowel disease. The available uncontrolled data show that it may be effective in steroid-resistant ulcerative colitis with a percentage of complete clinical remission of over 70% after an average of 4-6 weeks of therapy. The ad...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00860.x

    authors: Papa A,Danese S,Gasbarrini A,Gasbarrini G

    更新日期:2000-11-01 00:00:00

  • Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin.

    abstract:BACKGROUND:Helicobacter pylori eradication is a challenge in patients allergic to penicillin, especially those who have failed a first-eradication trial. AIM:To assess the efficacy and tolerability of H. pylori first-line treatment and rescue options in patients allergic to penicillin. METHODS:Prospective single cent...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02687.x

    authors: Gisbert JP,Gisbert JL,Marcos S,Olivares D,Pajares JM

    更新日期:2005-11-15 00:00:00

  • Twenty-four-hour intragastric acidity and nocturnal gastric secretion in gastric ulcer patients--the effects of cimetidine.

    abstract::In a double-blind randomized study, the profile of 24-h intragastric acidity and nocturnal gastric secretion was measured in a group of patients with healed gastric ulcer on placebo and 400 mg cimetidine b.d. and 800 mg nocte. Neither cimetidine regimen significantly decreased daytime intragastric acidity, but the 800...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00472.x

    authors: Derodra JK,Howden CW,Burget DW,Hunt RH

    更新日期:1990-06-01 00:00:00

  • Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.

    abstract:BACKGROUND:Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding. AIM:To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulate...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01682.x

    authors: Schiedermaier P,Koch L,Stoffel-Wagner B,Layer G,Sauerbruch T

    更新日期:2003-10-15 00:00:00

  • Randomised clinical trial: a 'nudge' strategy to modify endoscopic sedation practice.

    abstract:BACKGROUND:In behavioural economics, a 'nudge' describes configuration of a choice to encourage a certain action without taking away freedom of choice. AIM:To determine the impact of a 'nudge' strategy - prefilling either 3mL or 5mL syringes with midazolam - on endoscopic sedation practice. METHODS:Consecutive patien...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2011.04703.x

    authors: Harewood GC,Clancy K,Engela J,Abdulrahim M,Lohan K,O'Reilly C

    更新日期:2011-07-01 00:00:00

  • Review article: the management of autoimmune hepatitis beyond consensus guidelines.

    abstract:BACKGROUND:Consensus guidelines aid in the diagnosis and management of autoimmune hepatitis, but they are frequently based on low-quality clinical evidence, conflicting experiences and divergent opinions. Recommendations may be weak, discrepant or non-existent at critical decision points. AIMS:To identify the decision...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12381

    authors: Czaja AJ

    更新日期:2013-08-01 00:00:00

  • Effect of repeated capsaicin ingestion on intestinal chemosensation and mechanosensation.

    abstract:BACKGROUND:Ingestion of capsaicin reduces symptoms in functional dyspepsia but induces upper abdominal symptoms initially. AIMS:To evaluate the effects of one week of oral dosing with capsaicin on mechanonociception and chemonociception. METHODS:Healthy subjects ingested capsules containing 0.5 mg capsaicin t.d.s (n ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03022.x

    authors: Hammer J

    更新日期:2006-08-15 00:00:00

  • Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.

    abstract:BACKGROUND:Orlistat reduces energy uptake by the impairment of fat digestion and some evidence indicates it also lowers plasma cholesterol. AIM:To examine total, low-density lipoprotein- and high-density lipoprotein cholesterol during a weight reducing regimen, and assess the effect of orlistat in lowering cholesterol...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.01966.x

    authors: Erdmann J,Lippl F,Klose G,Schusdziarra V

    更新日期:2004-06-01 00:00:00

  • Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.

    abstract:BACKGROUND:Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS:To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paedi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.14194

    authors: Lucendo AJ,Arias-González L,Molina-Infante J,Arias Á

    更新日期:2017-08-01 00:00:00